ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KURA vs OBX // 10Y YIELD & FRED MACRO BETA

Kura Oncology Inc. (NASDAQ) VS. Obsidian Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: KURA 2 — OBX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KURA VS. OBX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KURA OBX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -7.53% -10.09% +2.56 KURA /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 25.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 26.00 -25.80 OBX /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 KURA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.9 55.3 -6.40 OBX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $912.7M $913.6M -$884.9K OBX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KURA REV OBX REV KURA GROSS % OBX GROSS % KURA FCF OBX FCF
FY 2025 $67.5M $295.9M — — -$70.7M -$90.5M
FY 2024 $53.9M $255.5M — — $133.8M -$75.8M
FY 2023 $464.3M — — — -$124.8M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KURA // BETA —
OBX // BETA —